Patents by Inventor C. Bennett

C. Bennett has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and their uses directed to cell growth and maintenance proteins
    Publication number: 20050186594
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of G protein-coupled receptor kinase 6. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding G protein-coupled receptor kinase 6. Methods of using these compounds for modulation of G protein-coupled receptor kinase 6 expression and for treatment of diseases associated with expression of G protein-coupled receptor kinase 6 are provided.
    Type: Application
    Filed: December 17, 2004
    Publication date: August 25, 2005
    Inventors: C. Bennett, Susan Freier, Nicholas Dean, Ian Popoff, Brett Monia, Donna Ward, Ming-Yi Chiang, Ravi Jain, Kenneth Dobie
  • Modulation of DC-SIGN expression
    Publication number: 20050182004
    Abstract: Compounds, compositions and methods are provided for modulating the expression of DC-SIGN. The compositions comprise oligonucleotides, targeted to nucleic acid encoding DC-SIGN. Methods of using these compounds for modulation of DC-SIGN expression and for diagnosis and treatment of diseases and conditions associated with expression of DC-SIGN are provided.
    Type: Application
    Filed: February 11, 2004
    Publication date: August 18, 2005
    Inventors: C. Bennett, Kenneth Dobie, Susan Gregory
  • Modulation of glucocorticoid receptor expression
    Publication number: 20050164271
    Abstract: Compounds, compositions and methods are provided for modulating the expression of glucocorticoid receptor. The compositions comprise oligonucleotides, targeted to nucleic acid encoding glucocorticoid receptor. Methods of using these compounds for modulation of glucocorticoid receptor expression and for diagnosis and treatment of diseases and conditions associated with expression of glucocorticoid receptor are provided.
    Type: Application
    Filed: January 20, 2005
    Publication date: July 28, 2005
    Inventors: Sanjay Bhanot, Kenneth Dobie, Susan Freier, Nicholas Dean, C. Bennett
  • Hepatocyte free uptake assays
    Publication number: 20050164209
    Abstract: The present invention provides methods of identifying an oligomeric compound having bioactivity in vivo, methods of identifying a small interfering RNA having bioactivity in vivo, and kits.
    Type: Application
    Filed: January 23, 2004
    Publication date: July 28, 2005
    Inventors: C. Bennett, Robert McKay, Brett Monia, Brenda Baker
  • Compositions and their uses directed to metabolic proteins
    Publication number: 20050164254
    Abstract: Compounds, compositions and methods are provided for modulating the expression of adipophilin. The compositions comprise oligonucleotides, targeted to nucleic acid encoding adipophilin. Methods of using these compounds for modulation of adipophilin expression and for diagnosis and treatment of diseases and conditions associated with expression of adipophilin are provided.
    Type: Application
    Filed: December 9, 2004
    Publication date: July 28, 2005
    Inventors: C. Bennett, Brett Monia, Nicholas Dean, Susan Freier, Sanjay Bhanot, Donna Ward, Alexander Borchers, Tamara Sipes, Kenneth Dobie, Ravi Jain
  • Compositions and their uses directed to transferases
    Publication number: 20050153925
    Abstract: Compounds, compositions and methods are provided for modulating the expression of hepatocyte growth factor receptor. The compositions comprise oligonucleotides, targeted to nucleic acid encoding hepatocyte growth factor receptor. Methods of using these compounds for modulation of hepatocyte growth factor receptor expression and for diagnosis and treatment of disease associated with expression of hepatocyte growth factor receptor are provided.
    Type: Application
    Filed: December 16, 2004
    Publication date: July 14, 2005
    Inventors: C. Bennett, Brett Monia, Nicholas Dean, Susan Freier, Brenda Baker, Donna Ward, William Gaarde, Lex Cowsert, Andrew Watt, Kenneth Dobie
  • Compositions and their uses directed to nucleic acid binding proteins
    Publication number: 20050153336
    Abstract: Compounds, compositions and methods are provided for modulating the expression of STAT2. The compositions comprise oligonucleotides, targeted to nucleic acid encoding STAT2. Methods of using these compounds for modulation of STAT2 expression and for diagnosis and treatment of diseases and conditions associated with expression of STAT2 are provided.
    Type: Application
    Filed: December 3, 2004
    Publication date: July 14, 2005
    Inventors: C. Bennett, Kenneth Dobie
  • Antisense modulation of interferon gamma receptor 2
    Publication number: 20050153924
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Interferon gamma receptor 2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Interferon gamma receptor 2. Methods of using these compounds for modulation of Interferon gamma receptor 2 expression and for treatment of diseases associated with expression of Interferon gamma receptor 2 are provided.
    Type: Application
    Filed: December 15, 2004
    Publication date: July 14, 2005
    Inventors: C. Bennett, Brett Monia, Susan Murray, Madeline Butler, Nicholas Dean, Rosanne Crooke, Mark Graham, Hong Zhang, Susan Freier, Brenda Baker, Eric Marcusson, Jacqueline Wyatt, Lex Cowsert, Kenneth Dobie, Andrew Watt
  • Modulation of RANKL expression
    Publication number: 20050148533
    Abstract: Compounds, compositions and methods are provided for modulating the expression of RANKL. The compositions comprise oligonucleotides, targeted to nucleic acid encoding RANKL. Methods of using these compounds for modulation of RANKL expression and for diagnosis and treatment of disease associated with expression of RANKL are provided.
    Type: Application
    Filed: September 17, 2004
    Publication date: July 7, 2005
    Inventors: Brenda Baker, C. Bennett, Kenneth Dobie, Kathleen Myers, Joshua Finger, Lex Cowsert
  • Antisense modulation of phospholipase A2, group IIA (synovial) expression
    Publication number: 20050143331
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Phospholipase A2, group IIA (synovial). The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Phospholipase A2, group IIA (synovial). Methods of using these compounds for modulation of Phospholipase A2, group IIA (synovial) expression and for treatment of diseases associated with expression of Phospholipase A2, group IIA (synovial) are provided.
    Type: Application
    Filed: August 18, 2003
    Publication date: June 30, 2005
    Inventors: C. Bennett, Jacqueline Wyatt
  • Microrna as ligands and target molecules
    Publication number: 20050142581
    Abstract: The present invention provides methods for the identification of target molecules that bind to ligands, particularly microRNA ligands and mimics thereof and/or microRNA target molecules and mimics thereof, with as little as millimolar (mM) affinity using mass spectrometry. The methods may be used to determine the mode of binding interaction between two or more of these target molecules to the ligand as well as their relative affinities. Also provided are methods for designing compounds having greater affinity to a ligand by identifying two or more target molecules using mass spectrometry methods of the invention and linking the target molecules together to form a novel compound.
    Type: Application
    Filed: September 3, 2004
    Publication date: June 30, 2005
    Inventors: Richard Griffey, C. Bennett, David Ecker, Donna Ward, Susan Freier
  • Antisense modulation of survivin expression
    Publication number: 20050143335
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Survivin. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Survivin. Methods of using these compounds for modulation of Survivin expression and for treatment of diseases associated with expression of Survivin are provided.
    Type: Application
    Filed: November 8, 2004
    Publication date: June 30, 2005
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: C. Bennett, Eric Swayze, Elizabeth Ackermann, Lex Cowsert
  • Antisense inhibition via RNAse H-independent reduction in mRNA
    Publication number: 20050130924
    Abstract: The present invention provides compositions and methods for reducing levels of a preselected mRNA, using antisense compounds targeted to a splice site or a region up to 50 nucleobases upstream of an exon/intron junction on said mRNA. Preferably, said antisense compounds do not elicit RNAse H cleavage of the mRNA.
    Type: Application
    Filed: September 24, 2004
    Publication date: June 16, 2005
    Inventors: Brett Monia, Susan Freier, Muthiah Manoharan, William Gaarde, Richard Griffey, Eric Swayze, C. Bennett
  • Modulation of CEACAM1 expression
    Publication number: 20050107324
    Abstract: Compounds, compositions and methods are provided for modulating the expression of CEACAM1. The compositions comprise oligonucleotides, targeted to nucleic acid encoding CEACAM1. Methods of using these compounds for modulation of CEACAM1 expression and for diagnosis and treatment of disease associated with expression of CEACAM1 are provided.
    Type: Application
    Filed: July 12, 2004
    Publication date: May 19, 2005
    Inventors: C. Bennett, Kenneth Dobie, Ravi Jain
  • Compositions and methods for the treatment of severe acute respiratory syndrome (SARS)
    Publication number: 20050100885
    Abstract: The present invention provides design and synthesis of oligomeric compounds and compositions that can be administered to reduce the activity of SARS virus in vivo or in vitro, to prevent or treat SARS virus-associated disease, to detect AARS virus, and to diagnose SARS virus-associated diseases.
    Type: Application
    Filed: April 26, 2004
    Publication date: May 12, 2005
    Inventors: Stanley Crooke, David Ecker, Rangarajan Sampath, Susan Freier, Christian Massire, Steven Hofstadler, Kristin Lowery, Eric Swayze, Brenda Baker, C. Bennett
  • Modulation of phosphodiesterase 4B expression
    Publication number: 20050101000
    Abstract: Compounds, compositions and methods are provided for modulating the expression of phosphodiesterase 4B. The compositions comprise oligonucleotides, targeted to nucleic acid encoding phosphodiesterase 4B. Methods of using these compounds for modulation of phosphodiesterase 4B expression and for diagnosis and treatment of disease associated with expression of phosphodiesterase 4B are provided.
    Type: Application
    Filed: December 11, 2002
    Publication date: May 12, 2005
    Inventors: C. Bennett, Kenneth Dobie
  • Antisense modulation of calreticulin expression
    Publication number: 20050101553
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of calreticulin. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding calreticulin. Methods of using these compounds for modulation of calreticulin expression and for treatment of diseases associated with expression of calreticulin are provided.
    Type: Application
    Filed: October 30, 2001
    Publication date: May 12, 2005
    Inventors: C. Bennett, Lex Cowsert
  • Modulation of aminopeptidase N expression
    Publication number: 20050075307
    Abstract: Compounds, compositions and methods are provided for modulating the expression of aminopeptidase N. The compositions comprise oligonucleotides, targeted to nucleic acid encoding aminopeptidase N. Methods of using these compounds for modulation of aminopeptidase N expression and for diagnosis and treatment of disease associated with expression of aminopeptidase N are provided.
    Type: Application
    Filed: July 12, 2004
    Publication date: April 7, 2005
    Inventors: C. Bennett, Ravi Jain
  • Antisense oligonucleotide modulation of tumor necrosis factor-alpha (TNF-alpha) expression
    Publication number: 20050053965
    Abstract: Compositions and methods are provided for inhibiting the expression of human tumor necrosis factor-? (TNF-?). Antisense oligonucleotides targeted to nucleic acids encoding TNF-? are preferred. Methods of using these oligonucleotides for inhibition of TNF-? expression and for treatment of diseases, particularly inflammatory and autoimmune diseases, associated with overexpression of TNF-? are provided.
    Type: Application
    Filed: February 2, 2004
    Publication date: March 10, 2005
    Inventors: Brenda Baker, C. Bennett
  • Antisense modulation of superoxide dismutase 1, soluble expression
    Publication number: 20050019915
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of superoxide dismutase 1, soluble. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding superoxide dismutase 1, soluble. Methods of using these compounds for modulation of superoxide dismutase 1, soluble expression and for treatment of diseases associated with expression of superoxide dismutase 1, soluble are provided.
    Type: Application
    Filed: September 26, 2003
    Publication date: January 27, 2005
    Inventors: C. Bennett, Kenneth Dobie